[ad_1]
Takeda’s PARP inhibitor ‘Zejula (ingredient name niraparib)’ confirmed the effect of improving consistent progression-free survival (PFS) as first-line maintenance therapy in ovarian cancer patients with residual disease after surgery of tumor reduction, and useful in cases of recurrence of high-risk groups.
Takeda presented data from the post-hoc analysis of PRIMA, a representative ‘Jezula’ clinician, at the American Society of Gynecologic Oncology (SGO 2021) Annual Conference held from 19-25.
The PRIMA study is a phase 3 clinical trial in which 733 adult patients with newly diagnosed ovarian cancer evaluated the effect of ‘Zejula’ maintenance therapy after platinum-based chemotherapy compared to placebo. Taking into account the high value, the efficacy of Jejula was confirmed dividing the time of surgery and the presence of residual diseases of the participating patients.
As a result, it was confirmed that ‘Jejula’ maintenance therapy reduced the risk of disease progression and death by 59% in patients with visible residual disease (VRD) who received additional tumor shrinkage surgery (IDS).
Since this group of patients has the highest risk of recurrence, treatment is known to be the most difficult among patients with newly diagnosed ovarian cancer.
Furthermore, ‘Jejula’ maintenance therapy reduced disease progression and risk of death by 42% in VRD patients after primary debulking surgery (PDS), and reduced disease progression and risk of death in patients without VRD after IDS. Reduced by 35%.
Furthermore, it was confirmed that the effect of ‘Jezula’ on residual diseases after PDS or IDS showed similar results between subgroups.
Professor Kim Jae-won from the Department of Obstetrics and Gynecology at Seoul National University Hospital said: “Ovarian cancer is stage 3 to 4 because there are no symptoms. More than 80% of patients experience a recurrence.” . “Especially for high-risk patients, it is important to choose more innovative treatment options,” he said.
Professor Kim said: “Jejula is already a primary and secondary maintenance therapy, which can be used independently of biomarkers in all patients, and is a PARP inhibitor approved as a treatment regimen of 4 or more.” It has been confirmed to be a drug that can expect groundbreaking maintenance therapy treatment effects even in high-risk, high-risk ovarian cancer patients, and is expected to play a critical role in the home ovarian cancer treatment environment “.
